Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Ovarian Neoplasms × Data Collection × Clear all

Status

Sponsor Class

OTHER 3 INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Papillomavirus Infections 9 Uterine Cervical Neoplasms 4 Neuroendocrine Tumors 4 Autoimmune Diseases 3 Prostatic Neoplasms 2 Neoplasms 2 Abortion, Spontaneous 2 Recurrence 1 Ovarian Neoplasms 1 Non-small Cell Lung Cancer Metastatic 1 Neuroblastoma 1 Neoplastic Cells, Circulating 1 Neoplasm Metastasis 1 Myasthenia Gravis 1 Lymphohistiocytosis, Hemophagocytic 1 Lung Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Brain Neoplasms 1

Interventions

Paclitaxel 93 Carboplatin 84 Bevacizumab 49 pembrolizumab 45 liposomal doxorubicin 45 olaparib 32 Gemcitabine 29 niraparib 25 Topotecan 23 Nivolumab 19 Cisplatin 17 Doxorubicin 14 Docetaxel 14 Drug Therapy 13 Cyclophosphamide 12 avelumab 11 1-dodecylpyridoxal 10 Fulvestrant 9 veliparib 8 atezolizumab 8 Cetuximab 8 oregovomab 7 mirvetuximab soravtansine 7 fluzoparib 7 Oxaliplatin 7 rucaparib 6 pazopanib 6 fludarabine 6 Temozolomide 6 Pemetrexed 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02262273 2017-03-01

OSCA

AstraZeneca

Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡